CCL8

Overview

CCL8 (C-C Motif Chemokine Ligand 8; also known as MCP-2) is a monocyte/macrophage chemoattractant chemokine. It is co-upregulated with CCL2, CCL7, and CCL13 in pretreatment melanoma biopsies from patients who do not respond to anti-PD-1 immunotherapy, forming part of the IPRES innate resistance transcriptional program.

Alterations observed in the corpus

• CCL8 was identified as a monocyte/macrophage chemoattractant up-regulated in non-responders to anti-PD-1 therapy in melanoma, part of the IPRES innate resistance transcriptional signature PMID:26997480.

Cancer types (linked)

• SKCM: CCL8 overexpression in pretreatment melanoma biopsies marks tumors resistant to anti-PD-1 therapy; co-expressed with CCL2, CCL7, CCL13 PMID:26997480.

Co-occurrence and mutual exclusivity

• Co-expressed with CCL2, CCL7, CCL13, VEGFA, VEGFC, IL10, and mesenchymal transition genes as part of the IPRES resistance signature in melanoma PMID:26997480.

Therapeutic relevance

• CCL8, as part of the IPRES signature, may help identify patients unlikely to benefit from anti-PD-1 monotherapy; targeting the chemokine-driven myeloid microenvironment is a proposed combination strategy PMID:26997480.

Open questions

• IPRES validation in independent prospective cohorts is required before clinical use PMID:26997480.

Sources

• PMID:26997480

This page was processed by crosslinker on 2026-05-14.